Equities researchers at Sidoti initiated coverage on shares of Mesa Laboratories (NASDAQ:MLAB) in a research note issued to investors on Wednesday, The Fly reports. The firm set a “neutral” rating on the medical instruments supplier’s stock.

Several other equities analysts also recently weighed in on MLAB. BidaskClub upgraded Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Thursday, November 15th. Zacks Investment Research upgraded Mesa Laboratories from a “hold” rating to a “buy” rating and set a $257.00 target price on the stock in a research report on Friday, February 8th. Finally, TheStreet upgraded Mesa Laboratories from a “c” rating to a “b-” rating in a research report on Friday, February 8th. Three equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $257.00.

NASDAQ MLAB opened at $232.71 on Wednesday. The firm has a market cap of $883.64 million, a P/E ratio of 37.66 and a beta of 0.38. The company has a current ratio of 1.57, a quick ratio of 1.20 and a debt-to-equity ratio of 0.25. Mesa Laboratories has a fifty-two week low of $131.51 and a fifty-two week high of $241.83.

Mesa Laboratories (NASDAQ:MLAB) last released its earnings results on Monday, February 4th. The medical instruments supplier reported $1.69 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.68 by $0.01. The company had revenue of $26.68 million for the quarter, compared to the consensus estimate of $25.80 million. Mesa Laboratories had a return on equity of 23.53% and a net margin of 9.98%. On average, equities research analysts anticipate that Mesa Laboratories will post 5.1 EPS for the current year.

In other news, Director Robert V. Dwyer sold 4,083 shares of the business’s stock in a transaction dated Monday, February 11th. The stock was sold at an average price of $235.03, for a total value of $959,627.49. Following the transaction, the director now directly owns 61,215 shares in the company, valued at $14,387,361.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Seg Ventures, Llc acquired 40,000 shares of the stock in a transaction dated Friday, December 21st. The stock was acquired at an average price of $24.75 per share, for a total transaction of $990,000.00. Following the completion of the transaction, the director now directly owns 120,000 shares of the company’s stock, valued at $2,970,000. The disclosure for this purchase can be found here. Insiders have sold 19,158 shares of company stock worth $4,450,329 over the last quarter. 15.00% of the stock is owned by company insiders.

Several institutional investors have recently made changes to their positions in the company. Conestoga Capital Advisors LLC lifted its position in shares of Mesa Laboratories by 2.3% in the fourth quarter. Conestoga Capital Advisors LLC now owns 486,256 shares of the medical instruments supplier’s stock valued at $101,331,000 after acquiring an additional 10,817 shares in the last quarter. BlackRock Inc. lifted its position in shares of Mesa Laboratories by 10.2% in the fourth quarter. BlackRock Inc. now owns 252,580 shares of the medical instruments supplier’s stock valued at $52,634,000 after acquiring an additional 23,384 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Mesa Laboratories by 2.1% in the third quarter. Vanguard Group Inc. now owns 161,627 shares of the medical instruments supplier’s stock valued at $30,000,000 after acquiring an additional 3,309 shares in the last quarter. Vanguard Group Inc lifted its position in shares of Mesa Laboratories by 2.1% in the third quarter. Vanguard Group Inc now owns 161,627 shares of the medical instruments supplier’s stock valued at $30,000,000 after acquiring an additional 3,309 shares in the last quarter. Finally, Ranger Investment Management L.P. lifted its position in shares of Mesa Laboratories by 75.4% in the fourth quarter. Ranger Investment Management L.P. now owns 157,019 shares of the medical instruments supplier’s stock valued at $32,721,000 after acquiring an additional 67,492 shares in the last quarter. Institutional investors and hedge funds own 76.33% of the company’s stock.

About Mesa Laboratories

Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.

Featured Article: Analyst Ratings Trading

The Fly

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.